Endeavor Stent’s Debut Drives 22% Growth In Medtronic Cardiovascular Biz

Medtronic's Endeavor zotarolimus-eluting coronary stent captured over 20% of the U.S. drug-eluting stent market by the tail end of the firm's fiscal fourth quarter (ended April 25), the company reported May 20